698 A.2d 959 (Del. Ch. 1996)
The case 'In re Caremark International Inc. Derivative Litigation' holds a pivotal position in corporate governance by delineating the duties of directors in monitoring corporate compliance programs.
Did the directors of Caremark International Inc. breach their fiduciary duty of care by failing to adequately oversee corporate compliance systems, thus allowing illegal activities to occur?
Directors may be liable for a breach of the duty of care if they fail to implement and utilize a reporting or information system or controls, known as a 'Caremark claim'. To establish director liability for oversight failure, it must be shown that the directors knew they were not discharging their fiduciary obligations or demonstrated a sustained or systematic failure to exercise oversight.
The court held that the directors of Caremark did not breach their duty of care. However, it emphasized that directors have a duty to make a good faith effort to implement and monitor a corporate compliance program as part of their fiduciary obligations.
The 'Caremark' decision introduced a critical standard for corporate governance, focusing on board members' fiduciary duties concerning oversight and monitoring of corporate compliance programs. It highlighted the necessity of implementing adequate information systems and redefined directors' liability concerning oversight failures. Despite the directors not being held liable in this case, the decision underscored their obligation to establish mechanisms that ensure legal compliance, which remains essential in contemporary corporate governance discussions, especially in industries with extensive regulatory frameworks.